Related Experiment Video
Updated: Feb 18, 2026

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
Published on: April 28, 2023
Copper(I) Chelators for Alzheimer's Disease
Stanley K A Opare1, Arvi Rauk1
1Department of Chemistry, University of Calgary , 2500 University Drive Northwest, Calgary, Alberta, Canada T2N 1N4.
Abstract:
A component of the neurotoxicity of the beta amyloid peptide (Aβ) of Alzheimer's disease is its ability to generate superoxide, hydrogen peroxide, and hydroxyl radicals by reaction of its reduced copper complex Aβ/Cu+ with molecular oxygen. The objective of the present work was to devise compounds, L, that could remove Cu+ from Aβ/Cu+, with the property that L/Cu+ itself would not be capable of reducing O2 or hydrogen peroxide. We show by density functional calculations that several pincer-type compounds with two imidazole rings and a sulfur or nitrogen have the desired combination of Cu+ binding affinity and Cu2+ reduction potential.
More Related Videos
11:04Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
Published on: September 7, 2019
06:17A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Related Concept Videos
Alzheimer's Disease: Treatment
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Dementia
The progression of dementia is generally gradual....
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Antidotes
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...